Tislelizumab, a new humanized IgG4 PD-1 inhibitor, was approved by China’s National Medical Products Administration (NMPA) in December 2019 for the treatment of classic relapsed or refractory Hodgkin’s lymphoma, locally advanced or metastatic urothelial carcinoma, non-small cell lung cancer, and hepatocarcinoma following at least second-line systemic chemotherapy (11). This evidence concerns the gene PDCD1 and Hodgkins lymphoma.